je.st
news
Tag: treatment
New Stem Cell Treatment Offers Dramatic Burn-Healing Potential
2017-06-13 14:00:00| TechNewsWorld
A med-tech startup has developed a novel way to treat burn wounds. RenovaCare harvests a variety of cells, including stem cells, from a healthy area of skin on a patient. Those cells are then suspended in a water-based solution and sprayed onto the wound using the company's SkinGun. "The sprayer allows us to have a generous distribution of cells," explained RenovaCare's Roger Esteban-Vives.
Tags: offers
potential
cell
treatment
Hatenboer-Water Supplies Fresh Water Treatment for Saga Cruise Vessel
2017-06-12 14:09:00| Ship Technology
Hatenboer-Water has been commissioned to supply water treatment equipment for two new cruise vessels currently under construction at the world renowned cruise vessel building shipyard Meyer Werft in Germany. The equipment conditions fresh water deriv
Tags: water
supplies
treatment
fresh
06.06.12 -- Ozone Gas Flow Monitoring For Water Treatment Systems
2017-02-08 10:00:59| chemicalonline News Articles
06/06/12Chemical Online Newsletter
Tags: systems
water
treatment
flow
FDA Accepts Two sBLAs for Mercks KEYTRUDA (pembrolizumab) for Locally Advanced or Metastatic Urothelial Cancer in Cisplatin-Ineligible First-Line and Second-Line Post-Platinum Failure Treatment Settings
2017-02-03 12:45:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA Also Receives Breakthrough Therapy Designation for Second-Line Treatment Based on KEYNOTE-045, Which Includes Primary Endpoints of Overall Survival and Progression-Free Survival KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental Biologics License Applications (sBLAs) for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in patients with locally advanced or metastatic urothelial cancer, a type of bladder cancer. Language: English Contact: For MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: advanced
treatment
settings
failure
European Commission Approves KEYTRUDA (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations
2017-01-31 22:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Approval Based on Data Showing Improved Overall Survival and Progression-Free Survival with KEYTRUDA Compared to Chemotherapy First Anti-PD-1 Therapy Approved in Europe for Previously Untreated Patients with Metastatic NSCLC KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK positive tumor mutations. Language: English Contact: For MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: high
positive
cell
treatment
Sites : [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] next »